Beech Hill Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5M Sell
22,975
-735
-3% -$163K 2.5% 5
2025
Q4
$5.42M Sell
23,710
-512
-2% -$117K 2.59% 6
2025
Q3
$5.61M Sell
24,222
-630
-3% -$128K 2.62% 8
2025
Q2
$4.61M Sell
24,852
-2,291
-8% -$426K 2.08% 10
2025
Q1
$5.69M Sell
27,143
-585
-2% -$114K 2.26% 8
2024
Q4
$4.93M Buy
27,728
+217
+0.8% +$39.9K 1.84% 15
2024
Q3
$5.43M Sell
27,511
-1,923
-7% -$359K 2.06% 12
2024
Q2
$5.05M Buy
29,434
+27
+0.1% +$4.47K 2.08% 12
2024
Q1
$5.36M Buy
29,407
+35
+0.1% +$6.03K 2.23% 11
2023
Q4
$4.55M Sell
29,372
-2,540
-8% -$370K 2.2% 11
2023
Q3
$4.76M Sell
31,912
-90
-0.3% -$13.2K 2.4% 9
2023
Q2
$4.31M Sell
32,002
-25
-0.1% -$3.67K 2.1% 14
2023
Q1
$5.1M Sell
32,027
-500
-2% -$76.4K 2.57% 7
2022
Q4
$5.26M Buy
32,527
+363
+1% +$55.7K 2.92% 4
2022
Q3
$4.32M Buy
32,164
+70
+0.2% +$10K 2.47% 8
2022
Q2
$4.92M Sell
32,094
-321
-1% -$49K 2.63% 6
2022
Q1
$5.25M Sell
32,415
-22,025
-40% -$3.2M 2.14% 13
2021
Q4
$7.37M Sell
54,440
-924
-2% -$109K 2.8% 8
2021
Q3
$5.97M Buy
55,364
+675
+1% +$77.1K 2.48% 12
2021
Q2
$6.16M Sell
54,689
-730
-1% -$82.2K 2.5% 11
2021
Q1
$6M Sell
55,419
-1,715
-3% -$183K 2.49% 13
2020
Q4
$6.12M Sell
57,134
-2,110
-4% -$203K 2.72% 10
2020
Q3
$5.19M Sell
59,244
-5,210
-8% -$491K 2.56% 12
2020
Q2
$6.33M Buy
64,454
+6,080
+10% +$535K 3.21% 6
2020
Q1
$4.45M Buy
58,374
+165
+0.3% +$14.1K 3.04% 9
2019
Q4
$5.15M Buy
58,209
+225
+0.4% +$18.7K 2.4% 19
2019
Q3
$4.39M Buy
57,984
+15,135
+35% +$1.04M 2.35% 20
2019
Q2
$3.12M Buy
42,849
+2,325
+6% +$183K 1.64% 31
2019
Q1
$3.27M Buy
40,524
+4,735
+13% +$387K 2.01% 26
2018
Q4
$3.3M Buy
35,789
+22,400
+167% +$1.97M 2.05% 26
2018
Q3
$1.27M Buy
13,389
+250
+2% +$23.7K 0.66% 40
2018
Q2
$1.22M Sell
13,139
-42,443
-76% -$4.15M 0.68% 38
2018
Q1
$5.26M Buy
55,582
+2,535
+5% +$278K 2.77% 14
2017
Q4
$5.13M Sell
53,047
-29,420
-36% -$2.77M 2.53% 12
2017
Q3
$7.33M Buy
82,467
+445
+0.5% +$33.9K 3.87% 3
2017
Q2
$5.95M Buy
82,022
+890
+1% +$59.8K 3.25% 4
2017
Q1
$5.29M Sell
81,132
-375
-0.5% -$23.6K 3.04% 4
2016
Q4
$5.1M Buy
81,507
+3,610
+5% +$220K 3.05% 5
2016
Q3
$4.91M Buy
77,897
+9,320
+14% +$603K 3.01% 10
2016
Q2
$4.25M Sell
68,577
-2,060
-3% -$126K 2.87% 12
2016
Q1
$4.04M Buy
70,637
+60
+0.1% +$3.34K 3.16% 13
2015
Q4
$4.18M Buy
70,577
+1,735
+3% +$99.9K 2.64% 12
2015
Q3
$3.75M Sell
68,842
-650
-0.9% -$42.3K 2.39% 14
2015
Q2
$4.67M Buy
69,492
+2,475
+4% +$162K 2.4% 18
2015
Q1
$3.92M Buy
67,017
+56,315
+526% +$3.4M 1.84% 22
2014
Q4
$700K Buy
10,702
+350
+3% +$22.1K 0.35% 49
2014
Q3
$598K Buy
10,352
+350
+3% +$19.4K 0.28% 66
2014
Q2
$565K Hold
10,002
0.25% 74
2014
Q1
$514K Buy
10,002
+350
+4% +$17.7K 0.24% 85
2013
Q4
$510K Hold
9,652
0.26% 74
2013
Q3
$432K Hold
9,652
0.23% 79
2013
Q2
$399K Buy
+9,652
New +$422K 0.23% 74

Other funds holding ABBV

Beech Hill Advisors's ABBV Position: Q1 2026 in Review

Beech Hill Advisors reduced its AbbVie (ABBV) stake by 3.1% in Q1 2026, selling an estimated $163K and leaving 22,975 shares worth $5M. The position accounts for 2.5% of the portfolio, ranked #5.

Beech Hill Advisors first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $7.37M in Q4 2021. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Beech Hill Advisors held 22,975 shares of AbbVie worth $5M as of Q1 2026.
  • Beech Hill Advisors sold 735 AbbVie shares in Q1 2026, an estimated $163K.
  • AbbVie made up 2.5% of Beech Hill Advisors's portfolio in Q1 2026, its #5 holding.
  • Beech Hill Advisors first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Beech Hill Advisors's AbbVie position peaked at $7.37M in Q4 2021.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Beech Hill Advisors's 13F filing for Q1 2026, filed 9 Apr 2026.